This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

Managing breast cancer across the continuum of care, including early breast cancer, metastatic disease, and survivorship is a complex and rapidly evolving task.